National Medical Insurance Bureau holds a special session on medical insurance support for innovative medical devices and drugs.

In order to implement the "Several Measures to Support the High-quality Development of Innovative Drugs" and promote the high-quality development of innovative drugs to better meet the diverse medical needs of the people, the National Medical Insurance Administration recently held a special investment session of the medical insurance to support innovative drugs and devices. Relevant comrades from the National Social Security Fund Council, China Investment Corporation, and other units, some financial institution experts, and some news media reporters attended the discussion on how to better support innovative drugs and devices, and put forward suggestions. Shi Zihai, member of the Party Group and Deputy Director of the National Medical Insurance Administration, presided over the discussion and delivered a speech. The participants unanimously agreed that China's innovative drugs and devices have great policy advantages, scientific research and intellectual advantages, industrial manufacturing advantages, and market potential. The National Medical Insurance Administration, together with relevant departments, issued "Several Measures," releasing a clear signal of the country's firm support for the development of innovative drugs and devices, providing strong support for the development of the Chinese innovative drugs and devices industry, and giving market confidence in the future development of the Chinese innovative drugs and devices industry.